Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Transl Res. 2015 Apr 29;167(1):214–227. doi: 10.1016/j.trsl.2015.04.011

Figure 4. Survival Plots.

Figure 4

Therapeutic targeting of innate inflammation pathways in BBDP rats delays/prevents T1D. Survival plots of BBDP rats after intraperitoneal delivery of interleukin-1 receptor antagonist (IL1RN, 350µg/kg/day, dash line), salbutamol (17.5µg/g five days per week, dash-dot line) and cromolyn (200µg/g five days per week, dot line). Control BBDP rats were treated daily with phosphate buffered saline (PBS, solid line). All treatments were initiated by 30 days of age. T1D onset was defined as the first of two consecutive days with fasting blood glucose ≥ 250mg/dl. The median age of survival in the saline-treated control group was 61 days (n=23, range 49–76 days), for IL1RN it was 67 days (n=16, range 53–100 days), for salbutamol it was 79 days (n=12, range 60–130 days) and for cromolyn it was 68 days (n=16, range 52–130 days). Significance based on log rank test, ** p<0.01, † p<0.0001.